Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP1 | P22413 | 3/20 | 0.64 |
| ▸ | KDR | P35968 | 10/20 | 0.63 |
| ▸ | FGFR1 | P11362 | 7/20 | 0.63 |
| ▸ | FLT1 | P17948 | 7/20 | 0.63 |
| ▸ | FGFR2 | P21802 | 4/20 | 0.63 |
| ▸ | FGFR4 | P22455 | 4/20 | 0.63 |
| ▸ | FGFR3 | P22607 | 4/20 | 0.63 |
| ▸ | FLT4 | P35916 | 4/20 | 0.63 |
| ▸ | PDGFRB | P09619 | 5/20 | 0.59 |
| ▸ | EGFR | P00533 | 3/20 | 0.59 |
| ▸ | SRC | P12931 | 1/20 | 0.49 |
| ▸ | EPHA2 | P29317 | 3/20 | 0.43 |
| ▸ | EPHB4 | P54760 | 3/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6489428 | 0.94 | ENPP1 (0.62) | ENPP1KDRFGFR1FLT1FGFR2 | |
| SCHEMBL4427378 | 0.81 | FGFR1 (0.55) | ENPP1KDRFGFR1FLT1FGFR2 | |
| SCHEMBL4373545 | 0.81 | EGFR (0.65) | ENPP1KDRFGFR1FLT1PDGFRB | |
| SCHEMBL5501477 | 0.80 | FGFR4 (0.52) | ENPP1KDRFGFR1FLT1FGFR2 | |
| SCHEMBL7455925 | 0.80 | ENPP1 (0.65) | ENPP1KDRFGFR1FLT1FGFR2 | |
| SCHEMBL4178028 | 0.79 | ENPP1 (0.67) | ENPP1KDRFGFR1FLT1FLT4 | |
| SCHEMBL30408709 | 0.79 | ENPP1 (0.67) | ENPP1KDRFGFR1FLT1FLT4 | |
| SCHEMBL18744742 | 0.79 | ENPP1 (0.67) | ENPP1KDRFGFR1FLT1FLT4 | |
| SCHEMBL1013051 | 0.79 | ENPP1 (0.79) | ENPP1KDRFGFR1FLT1FLT4 | |
| SCHEMBL662795 | 0.79 | ENPP1 (0.79) | ENPP1KDRFGFR1FLT1FLT4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7262201-B1 | For the manufacture of a medicament for use in the production of an antiangiogenic and/or vascular permeability reducing effect in warm-blooded animals | ASTRAZENECA AB (SE) | 2007-08-28 | — | — | US | disclosed |
| EP-1005470-B1 | OXINDOLYLQUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS | ASTRAZENECA AB (SE) | 2007-08-01 | — | — | EP | disclosed |
| EP-1119567-B1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2005-05-04 | — | — | EP | disclosed |
| US-6294532-B1 | TREATMENT OF A NUMBER OF DISEASE STATES INCLUDING CANCER AND RHEUMATOID ARTHRITIS. | ZENECA LIMITED (GB) | 2001-09-25 | — | — | US | disclosed |
| EP-1119567-A1 | QUINAZOLINE DERIVATIVES | AstraZeneca AB (SE) | 2001-08-01 | — | — | EP | disclosed |
| EP-1005470-A1 | OXINDOLYLQUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS | ZENECA LIMITED (GB) | 2000-06-07 | — | — | EP | disclosed |
| WO-2000021955-A1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2000-04-20 | — | — | WO | disclosed |
| WO-1999010349-A1 | OXINDOLYLQUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS | ZENECA LIMITED (GB) | 1999-03-04 | — | — | WO | disclosed |
| EP-0873319-A1 | QUINAZOLINE DERIVATIVES | ZENECA LIMITED (GB) | 1998-10-28 | — | — | EP | disclosed |
| WO-1997022596-A1 | QUINAZOLINE DERIVATIVES | ZENECA LIMITED (GB) | 1997-06-26 | — | — | WO | disclosed |